[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fOkWZgOntwlf2t3VUv4dTXgZMhk9NKVdTf-j3srTBEXs":8,"$fakEzk-rTKrNZgejyojjW0EbkIEFa1MgiWe2FRBiQCH8":55,"$fyYErX5LkBXyOcws49hxRo6aHXLRz_G_SnPGyFmUmhZE":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},67652,867514,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//nqL2t0ch6TCNrtDdNzheeMcnEUqvRosA.png","关明","上海高博肿瘤医院","肿瘤科","副主任医师",77,0,"全面了解EGFR L858突变IVA期用药细节指南","","https://ystcdn.venuertc.com/venue/AI/46fcb126-097d-46ce-b400-5552f6d090aa.jpg","\u003C!--全面了解肺癌EGFR L858突变IVA期药品使用指南-->\n\u003Cdiv class=\"custom-material-wrap\">\n\n  \u003Ch1 id=\"material_title\" class=\"custom-material-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">全面了解EGFR L858突变IVA期用药细节指南\u003C/h1>\n\n  \u003Cdiv class=\"custom-material-section custom-material-bg1\">\n    \u003Ch2 class=\"custom-material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 EGFR靶向与辅助用药：基本认知\u003C/h2>\n    \u003Cp class=\"custom-material-text\">\n      EGFR（表皮生长因子受体）L858突变是治疗中常见的基因变异类型，选用的药物多为EGFR酪氨酸激酶抑制剂（TKI）、免疫治疗药物，以及对症辅助类药物。本文将详细介绍这几类药物的 \u003Cspan class=\"custom-material-highlight\">核心用法与关键注意事项\u003C/span>，覆盖服药时间、剂型技巧、不良反应处理、储存细节等7大方面 📝。每点都关乎治疗效果和安全，一定要细致了解。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-material-section custom-material-bg2\">\n    \u003Ch2 class=\"custom-material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 用药时间与方法：什么时候、怎么吃？\u003C/h2>\n    \u003Cp class=\"custom-material-text\">\n      \u003Cspan class=\"custom-material-emoji\">⏰\u003C/span> \u003Cb>EGFR抑制剂（如吉非替尼、厄洛替尼等）\u003C/b>\n      \u003Cbr>\n      - 通常建议每日一次，固定时间服用更利于药效稳定。\n      \u003Cbr>\n      - 说明书提示：吉非替尼可餐前或餐后服用；厄洛替尼需空腹服用，即服药前后1小时不进食。\n      \u003Cbr>\n      - \u003Cspan class=\"custom-material-highlight\">正确做法：\u003C/span> 按说明书要求安排服药时间，避免因进食影响药物吸收。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-emoji\">🍽️\u003C/span> \u003Cb>胃酸抑制剂（如艾普拉唑、奥美拉唑）\u003C/b>\n      \u003Cbr>\n      - 推荐早晨空腹或饭前30分钟服用，以最大化抑酸效果。\n      \u003Cbr>\n      - 胃药与TKI间隔至少2小时，以减少相互影响。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-emoji\">💊\u003C/span> \u003Cb>免疫治疗药物（如PD-1抑制剂）\u003C/b>\n      \u003Cbr>\n      - 静脉输注形式，严格遵循医嘱，无需家庭自服操作。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-hint\">小建议：\u003C/span> 建议使用手机提醒服药，减少漏服风险。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-material-section custom-material-bg3\">\n    \u003Ch2 class=\"custom-material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 剂型与服用技巧：不同药品的用法小窍门\u003C/h2>\n    \u003Cp class=\"custom-material-text\">\n      \u003Cspan class=\"custom-material-emoji\">💡\u003C/span> \u003Cb>EGFR抑制剂（片剂/胶囊）\u003C/b>\n      \u003Cbr>\n      - 片剂需整片吞服，勿掰开、嚼碎或溶于水，如吉非替尼、厄洛替尼等。\n      \u003Cbr>\n      - 必须用温水送服，避免热水或冷饮。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-emoji\">🥤\u003C/span> \u003Cb>止吐药（如昂丹司琼片）\u003C/b>\n      \u003Cbr>\n      - 根据说明书，餐前或胃不适时服用。建议整片吞服，勿自行加量。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-emoji\">🧃\u003C/span> \u003Cb>维生素补充剂\u003C/b>\n      \u003Cbr>\n      - 通常与餐同服，助于吸收，勿超量。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-hint\">服药技巧：\u003C/span> 若吞咽有困难，可尝试用少量稠粥辅助服用，但勿碾碎药片。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-material-section custom-material-bg4\">\n    \u003Ch2 class=\"custom-material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 药物相互作用：哪些药不能一起吃？\u003C/h2>\n    \u003Cp class=\"custom-material-text\">\n      \u003Cspan class=\"custom-material-emoji\">🔗\u003C/span> \u003Cb>EGFR抑制剂与胃酸抑制剂\u003C/b>\n      \u003Cbr>\n      - 酪氨酸激酶抑制剂在酸性环境吸收更好，胃药（如奥美拉唑、艾普拉唑）会降低TKI药物浓度，影响疗效（Mok et al., JCO, 2009）。\n      \u003Cbr>\n      - \u003Cspan class=\"custom-material-highlight\">正确做法：\u003C/span> 合理安排间隔时间，两药服用时间错开至少2小时。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-emoji\">🚫\u003C/span> \u003Cb>免疫治疗药物与强效免疫抑制剂\u003C/b>\n      \u003Cbr>\n      - 如需联合用药，必须在医生指导下进行，避免互相抵消疗效。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-emoji\">❗\u003C/span> \u003Cb>抗肿瘤辅助药与其它药物\u003C/b>\n      \u003Cbr>\n      - 某些辅助制剂（如保肝药、维生素）可能微调肝酶或胃肠动力，酌情安排与主体药物间距。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-hint\">小结：\u003C/span> 用药前留意说明书相互作用条目，务必咨询药师或医生。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-material-section custom-material-bg5\">\n    \u003Ch2 class=\"custom-material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 特殊人群用药调整：老年人、肝肾功能异常怎么办？\u003C/h2>\n    \u003Cp class=\"custom-material-text\">\n      \u003Cspan class=\"custom-material-emoji\">👴\u003C/span> \u003Cb>老年人用药\u003C/b>\n      \u003Cbr>\n      - 通常起始剂量不需调整，但密切监测不良反应。\n      \u003Cbr>\n      - 68岁男性患者使用EGFR抑制剂后效果稳定，无明显副作用，但服药期间注意定期检测肝肾指标。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-emoji\">🩺\u003C/span> \u003Cb>肝、肾功能异常者\u003C/b>\n      \u003Cbr>\n      - 某些药物（如TKI、免疫药物）需监测肝酶、肌酐等，重度肝肾损害情况下慎用或调整剂量。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-emoji\">🤰\u003C/span> \u003Cb>孕妇、哺乳期\u003C/b>\n      \u003Cbr>\n      - 多数药品无足够安全数据，必须避免或严格遵医嘱。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-hint\">特别提醒：\u003C/span> 所有用药调整均应结合专业医师指导，勿自行更改药量。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-material-section custom-material-bg6\">\n    \u003Ch2 class=\"custom-material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 常见不良反应：有哪些副作用？如何处理？\u003C/h2>\n    \u003Cp class=\"custom-material-text\">\n      \u003Cspan class=\"custom-material-emoji\">⚠️\u003C/span> \u003Cb>EGFR抑制剂\u003C/b>\n      \u003Cbr>\n      - 说明书显示：最常见不良反应为皮疹（20-40%）、腹泻、肝酶升高等。\u003Cbr>\n      - 出现皮疹时可用外用药缓解，严重腹泻则减量或暂缓服药，并及时联系医生（Yang et al., Lancet Oncol, 2015）。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-emoji\">🤢\u003C/span> \u003Cb>止吐药\u003C/b>\n      \u003Cbr>\n      - 可能产生头晕、便秘等反应，剂量勿超标，必要时调整药物。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-emoji\">🟡\u003C/span> \u003Cb>免疫治疗药物\u003C/b>\n      \u003Cbr>\n      - 不良反应如疲劳、食欲减退等，多数可自缓，严重不适需就医。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-hint\">正确做法：\u003C/span> 监测身体变化，遇到持续性或剧烈副作用，第一时间告知医护人员。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-material-section custom-material-bg7\">\n    \u003Ch2 class=\"custom-material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 储存条件与有效期：如何保存药品？\u003C/h2>\n    \u003Cp class=\"custom-material-text\">\n      \u003Cspan class=\"custom-material-emoji\">📦\u003C/span> \u003Cb>储存环境\u003C/b>\n      \u003Cbr>\n      - 绝大部分EGFR抑制剂、辅助药物要求置于干燥、阴凉处，温度控制在15-25℃较为适宜。避免阳光直射和潮湿。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-emoji\">📅\u003C/span> \u003Cb>有效期管理\u003C/b>\n      \u003Cbr>\n      - 开封后药品需严格按说明书保存，未用完的药物按原包装密封存放。\n      \u003Cbr>\n      - \u003Cspan class=\"custom-material-highlight\">特别提醒：\u003C/span> 若药品已过有效期或出现变色、异味、裂片等情况，必须弃用，不可继续服用。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-emoji\">🗑️\u003C/span> \u003Cb>过期药品处理\u003C/b>\n      \u003Cbr>\n      - 请按社区规范丢弃，不要随垃圾混杂，防止污染。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-material-section custom-material-bg8\">\n    \u003Ch2 class=\"custom-material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 漏服与过量处理：出问题该怎么应对？\u003C/h2>\n    \u003Cp class=\"custom-material-text\">\n      \u003Cspan class=\"custom-material-emoji\">🚨\u003C/span> \u003Cb>漏服药物\u003C/b>\n      \u003Cbr>\n      - 若忘记一次EGFR抑制剂，可补服最近一次，但勿加倍服用。\n      \u003Cbr>\n      - 其它辅助药漏服，原则上顺延至下次，无需补量。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-emoji\">☠️\u003C/span> \u003Cb>过量服用\u003C/b>\n      \u003Cbr>\n      - 过量会出现明显副作用，如严重皮疹、腹泻等。\u003Cbr>\n      \u003Cspan class=\"custom-material-highlight\">正确做法：\u003C/span> 若误服过量，尽快联系医生，必要时送医处理。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-material-section custom-material-bg9\">\n    \u003Ch2 class=\"custom-material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 典型用药经验分享\u003C/h2>\n    \u003Cp class=\"custom-material-text\">\n      \u003Cspan class=\"custom-material-emoji\">🔬\u003C/span> 临床实践中，68岁男性患者连续使用EGFR酪氨酸激酶抑制剂，每日固定时间服药，副作用轻微。未出现严重肝肾损伤，期间胃酸抑制剂安排与TKI错开服用，避免了药效降低风险。服药期间严格监测肝肾功能，确保安全。\n    \u003C/p>\n    \u003Cp class=\"custom-material-text\">\n      \u003Cspan class=\"custom-material-emoji\">🩹\u003C/span> 另一位患者服用止吐药后出现轻微头晕，及时告知医护后调整药量，副作用明显减轻。\n    \u003C/p>\n    \u003Cp class=\"custom-material-text\">\n      \u003Cspan class=\"custom-material-emoji\">💧\u003C/span> 服用维生素补充剂按餐吃，不出现胃部不适，服药便捷、吸收较好。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-material-section custom-material-bg10\">\n    \u003Ch2 class=\"custom-material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10 总结与安全提示\u003C/h2>\n    \u003Cp class=\"custom-material-text\">\n      \u003Cspan class=\"custom-material-emoji\">✅\u003C/span> EGFR L858突变IVA期涉及的药物种类较多，\u003Cspan class=\"custom-material-highlight\">最关键在于合理安排服药时间、用量\u003C/span>，注意药物相互作用并警惕副作用发生。服药期间建议每月监测肝肾指标，严格遵守说明书与医嘱。\n      \u003Cbr>\u003Cbr>\n      \u003Cspan class=\"custom-material-emoji\">🛡️\u003C/span> 最后，遇到异常反应或不确定情况，要及时联系医生或药师，不可自行加减药量或盲目停药。合理用药，是保障疗效和安全的基础。\n    \u003C/p>\n  \u003C/div>\n\n  \u003Cdiv class=\"custom-material-section custom-material-bg11\">\n    \u003Ch2 class=\"custom-material-subtitle\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">11 参考文献（APA格式）\u003C/h2>\n    \u003Cul class=\"custom-material-text\">\n      \u003Cli>\n        Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., ... & Fukuoka, M. (2009). Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. \u003Ci>Journal of Clinical Oncology, 27\u003C/i>(25), 4336-4343.\n      \u003C/li>\n      \u003Cli>\n        Yang, J. C. H., Wu, Y. L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., ... & Mok, T. S. (2015). Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation–positive advanced non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomized controlled trial. \u003Ci>Lancet Oncology, 16\u003C/i>(4), 425-435.\n      \u003C/li>\n      \u003Cli>\n        Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., ... & Brahmer, J. R. (2016). Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. \u003Ci>New England Journal of Medicine, 375\u003C/i>(19), 1823-1833.\n      \u003C/li>\n    \u003C/ul>\n  \u003C/div>\n\n\u003C/div>\n\n\u003Cstyle>\n.custom-material-wrap {\n  max-width: 860px;\n  margin: 40px auto;\n  background: #f7fcfd;\n  border-radius: 14px;\n  box-shadow: 0 2px 10px rgba(70,120,175,0.08);\n  padding: 36px 40px 30px 40px;\n  font-family: 'HarmonyOS Sans', 'Helvetica Neue', Arial, 'PingFang SC', 'Microsoft Yahei', sans-serif;\n  box-sizing: border-box;\n}\n.custom-material-title {\n  font-size: 34px;\n  font-weight: 700;\n  color: #215e6a;\n  text-align: center;\n  margin-bottom: 32px;\n  letter-spacing: .5px;\n}\n.custom-material-section {\n  margin-bottom: 28px;\n  border-radius: 12px;\n  padding: 28px 28px 18px 28px;\n  box-sizing: border-box;\n  box-shadow: 0 3px 12px rgba(170,195,220,0.08);\n}\n.custom-material-subtitle {\n  font-size: 24px;\n  font-weight: 600;\n  color: #236278;\n  margin-bottom: 20px;\n  background: linear-gradient(90deg,#d8eff6 85%,transparent 100%);\n  border-radius: 8px;\n  padding: 12px 16px 11px 16px;\n  letter-spacing: .4px;\n  box-sizing: border-box;\n}\n.custom-material-text {\n  font-size: 16px;\n  color: #3a4c5c;\n  line-height: 2em;\n  margin: 0 0 8px 0;\n  letter-spacing: .07em;\n}\n.custom-material-highlight {\n  background: #dbf0e1;\n  color: #20835f;\n  font-weight: 600;\n  border-radius: 4px;\n  padding: 0 4px;\n}\n.custom-material-hint {\n  color:#5497bc;\n  font-size:15px;\n  background: #ebf5fb;\n  border-radius: 6px;\n  padding:0 5px;\n  margin-left:2px;\n}\n.custom-material-emoji {\n  font-size: 22px;\n  vertical-align: middle;\n  margin-right: 4px;\n}\n.custom-material-bg1 {background: linear-gradient(112deg, #e8f5fc 60%, #fafdf9 100%);}\n.custom-material-bg2 {background: linear-gradient(98deg, #e1ebf8 70%, #f7faf7 100%);}\n.custom-material-bg3 {background: linear-gradient(115deg, #ecf7ef 70%, #fafdfe 100%);}\n.custom-material-bg4 {background: linear-gradient(120deg, #eaf6f4 60%, #fdfffd 100%);}\n.custom-material-bg5 {background: linear-gradient(104deg, #e7f5fa 70%, #f9fdfb 100%);}\n.custom-material-bg6 {background: linear-gradient(110deg, #e6f2f6 56%, #fafff9 100%);}\n.custom-material-bg7 {background: linear-gradient(116deg, #ebf5ee 60%, #fafdfb 100%);}\n.custom-material-bg8 {background: linear-gradient(94deg, #e8f5fa 70%, #fafdfc 100%);}\n.custom-material-bg9 {background: linear-gradient(120deg, #e9f3fa 60%, #fafcfb 100%);}\n.custom-material-bg10{background: linear-gradient(120deg, #eaf7f3 60%, #fafcfb 100%);}\n.custom-material-bg11{background: linear-gradient(118deg, #efeffb 68%, #fcfddb 100%);}\nul.custom-material-text {\n  margin: 8px 0 0 22px;\n  padding: 0;\n  font-size: 15px;\n  color: #3a4c5c;\n}\nul.custom-material-text li {\n  margin-bottom: 10px;\n  line-height: 1.7em;\n}\n@media screen and (max-width:670px){\n  .custom-material-wrap{padding:18px 6px 18px 6px;}\n  .custom-material-title{font-size:28px;}\n  .custom-material-section{padding:18px 12px 12px 12px;}\n  .custom-material-subtitle{font-size:18px;padding:9px 9px 8px 9px;}\n}\n\u003C/style>\n","\u003C!--全面了解肺癌EGFR L858突变IVA期药品使用指南-->\n\u003Cdiv class=\"custom-material-wrap\">\n\n  \u003Ch1 id=\"material_title\" cla",529,"2025-10-10 16:55:40","EGFR突变, 肺癌药物使用, EGFR酪氨酸激酶抑制剂, 不良反应处理, 用药指南, 免疫治疗药物, 老年患者用药, 药物相互作用","本指南深入解析EGFR L858突变患者的药物使用细节，涵盖EGFR靶向药物、使用时间、服用方法及不良反应处理，帮助患者更安全有效地管理治疗。适合肺癌患者及其家属了解。","2025-10-21 12:30:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]